CD37: Leukocyte antigen CD37
Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on CD37, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Antibody-drug conjugate 1
- Other 1
| BI-836826 | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Other | InhibitorLeukocyte antigen CD37 inhibitor | 0 |
| Naratuximab emtansine | Phase 2 | AbbVie | Antibody-drug conjugate | Binding agentLeukocyte antigen CD37 binding agent | 0 |
| Otlertuzumab | Phase 2 | Aptevo Therapeutics | Antibody | Binding agentLeukocyte antigen CD37 binding agent | 0 |
- Diffuse large B-cell lymphoma0.13
- Systemic lupus erythematosus0.12
- Non-Hodgkin lymphoma0.11
- Acute myeloid leukemia0.11
- Neoplasm0.11
- B-cell chronic lymphocytic leukemia0.10
- Lymphoma0.10
- B-cell non-Hodgkin lymphoma0.09
- Glioma0.07
- Central nervous system cancer0.07
- Mature T-cell and NK-cell non-Hodgkin lymphoma0.07
- Non-alcoholic fatty liver0.07
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712880, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P11049, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets